98 related articles for article (PubMed ID: 27016236)
1. A SNaPshot of potentially personalized care: Molecular diagnostics in gynecologic cancer.
Penson RT; Sales E; Sullivan L; Borger DR; Krasner CN; Goodman AK; del Carmen MG; Growdon WB; Schorge JO; Boruta DM; Castro CM; Dizon DS; Birrer MJ
Gynecol Oncol; 2016 Apr; 141(1):108-12. PubMed ID: 27016236
[TBL] [Abstract][Full Text] [Related]
2. Tissue-specific signatures of activating PIK3CA and RAS mutations in carcinosarcomas of gynecologic origin.
Growdon WB; Roussel BN; Scialabba VL; Foster R; Dias-Santagata D; Iafrate AJ; Ellisen LW; Tambouret RH; Rueda BR; Borger DR
Gynecol Oncol; 2011 Apr; 121(1):212-7. PubMed ID: 21168197
[TBL] [Abstract][Full Text] [Related]
3. Impact of somatic molecular profiling on clinical trial outcomes in rare epithelial gynecologic cancer patients.
Rodriguez-Freixinos V; Lheureux S; Mandilaras V; Clarke B; Dhani NC; Mackay H; Butler MO; Wang L; Siu LL; Kamel-Reid S; Stockley T; Bedard PL; Oza AM
Gynecol Oncol; 2019 May; 153(2):304-311. PubMed ID: 30792002
[TBL] [Abstract][Full Text] [Related]
4. Novel molecular insights from routine genotyping of colorectal carcinomas.
Stachler MD; Rinehart E; Lindeman N; Odze R; Srivastava A
Hum Pathol; 2015 Apr; 46(4):507-13. PubMed ID: 25683705
[TBL] [Abstract][Full Text] [Related]
5. Multiplex mutation screening by mass spectrometry evaluation of 820 cases from a personalized cancer medicine registry.
Beadling C; Heinrich MC; Warrick A; Forbes EM; Nelson D; Justusson E; Levine J; Neff TL; Patterson J; Presnell A; McKinley A; Winter LJ; Dewey C; Harlow A; Barney O; Druker BJ; Schuff KG; Corless CL
J Mol Diagn; 2011 Sep; 13(5):504-13. PubMed ID: 21726664
[TBL] [Abstract][Full Text] [Related]
6. Initiation of a formalized precision medicine program in gynecologic oncology.
Gunderson CC; Rowland MR; Wright DL; Andrade KL; Mannel RS; McMeekin DS; Moore KN
Gynecol Oncol; 2016 Apr; 141(1):24-8. PubMed ID: 27016225
[TBL] [Abstract][Full Text] [Related]
7. PIK3CA and PTEN gene and exon mutation-specific clinicopathologic and molecular associations in colorectal cancer.
Day FL; Jorissen RN; Lipton L; Mouradov D; Sakthianandeswaren A; Christie M; Li S; Tsui C; Tie J; Desai J; Xu ZZ; Molloy P; Whitehall V; Leggett BA; Jones IT; McLaughlin S; Ward RL; Hawkins NJ; Ruszkiewicz AR; Moore J; Busam D; Zhao Q; Strausberg RL; Gibbs P; Sieber OM
Clin Cancer Res; 2013 Jun; 19(12):3285-96. PubMed ID: 23633456
[TBL] [Abstract][Full Text] [Related]
8. Molecular landscape of ERBB2/HER2 gene amplification among patients with gynecologic malignancies; clinical implications and future directions.
Nasioudis D; Gysler S; Latif N; Cory L; Giuntoli RL; Kim SH; Simpkins F; Martin L; Ko EM
Gynecol Oncol; 2024 Jan; 180():1-5. PubMed ID: 38029652
[TBL] [Abstract][Full Text] [Related]
9. Identification of uncommon PIK3CA mutations in lung cancer by using pyrosequencing.
Schildgen V; Lüsebrink J; Appel JD; Wübben C; Engel-Riedel W; Ludwig C; Stoelben E; Schildgen O; Brockmann M
Diagn Mol Pathol; 2013 Mar; 22(1):22-7. PubMed ID: 23370426
[TBL] [Abstract][Full Text] [Related]
10. Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases.
Baldus SE; Schaefer KL; Engers R; Hartleb D; Stoecklein NH; Gabbert HE
Clin Cancer Res; 2010 Feb; 16(3):790-9. PubMed ID: 20103678
[TBL] [Abstract][Full Text] [Related]
11. Mutation of the PIK3CA gene in ovarian and breast cancer.
Campbell IG; Russell SE; Choong DY; Montgomery KG; Ciavarella ML; Hooi CS; Cristiano BE; Pearson RB; Phillips WA
Cancer Res; 2004 Nov; 64(21):7678-81. PubMed ID: 15520168
[TBL] [Abstract][Full Text] [Related]
12. Low incidence of KRAS, BRAF, and PIK3CA mutations in adenocarcinomas of the ampulla of Vater and their prognostic value.
Kwon MJ; Kim JW; Jung JP; Cho JW; Nam ES; Cho SJ; Kim JS; Park HR; Min SK; Seo J; Min KW; Kim DH; Jeon JY
Hum Pathol; 2016 Apr; 50():90-100. PubMed ID: 26997442
[TBL] [Abstract][Full Text] [Related]
13. PIK3CA missense mutation is associated with unfavorable outcome in grade 3 endometrioid carcinoma but not in serous endometrial carcinoma.
McIntyre JB; Nelson GS; Ghatage P; Morris D; Duggan MA; Lee CH; Doll CM; Köbel M
Gynecol Oncol; 2014 Jan; 132(1):188-93. PubMed ID: 24262879
[TBL] [Abstract][Full Text] [Related]
14. Rare mutations in the PIK3CA gene contribute to aggressive endometrial cancer.
Konstantinova D; Kaneva R; Dimitrov R; Savov A; Ivanov S; Dyankova T; Kremensky I; Mitev V
DNA Cell Biol; 2010 Feb; 29(2):65-70. PubMed ID: 19839777
[TBL] [Abstract][Full Text] [Related]
15. Unique Genetic and Survival Characteristics of Invasive Mucinous Adenocarcinoma of the Lung.
Shim HS; Kenudson M; Zheng Z; Liebers M; Cha YJ; Hoang Ho Q; Onozato M; Phi Le L; Heist RS; Iafrate AJ
J Thorac Oncol; 2015 Aug; 10(8):1156-62. PubMed ID: 26200269
[TBL] [Abstract][Full Text] [Related]
16. Identification and clinical significance of somatic oncogenic mutations in epithelial ovarian cancer.
Watanabe T; Nanamiya H; Endo Y; Kojima M; Nomura S; Furukawa S; Soeda S; Tamura H; Ryufuku M; Tanaka D; Isogai T; Imai JI; Watanabe S; Fujimori K
J Ovarian Res; 2021 Oct; 14(1):129. PubMed ID: 34615547
[TBL] [Abstract][Full Text] [Related]
17. PPP2R1A mutations are common in the serous type of endometrial cancer.
Nagendra DC; Burke J; Maxwell GL; Risinger JI
Mol Carcinog; 2012 Oct; 51(10):826-31. PubMed ID: 21882256
[TBL] [Abstract][Full Text] [Related]
18. Correlation between activation of PI3K/AKT/mTOR pathway and prognosis of breast cancer in Chinese women.
Deng L; Chen J; Zhong XR; Luo T; Wang YP; Huang HF; Yin LJ; Qiu Y; Bu H; Lv Q; Zheng H
PLoS One; 2015; 10(3):e0120511. PubMed ID: 25816324
[TBL] [Abstract][Full Text] [Related]
19. Phase II basket trial of perifosine monotherapy for recurrent gynecologic cancer with or without PIK3CA mutations.
Hasegawa K; Kagabu M; Mizuno M; Oda K; Aoki D; Mabuchi S; Kamiura S; Yamaguchi S; Aoki Y; Saito T; Yunokawa M; Takehara K; Okamoto A; Ochiai K; Kimura T
Invest New Drugs; 2017 Dec; 35(6):800-812. PubMed ID: 28864978
[TBL] [Abstract][Full Text] [Related]
20. Clinical next generation sequencing to identify actionable aberrations in a phase I program.
Boland GM; Piha-Paul SA; Subbiah V; Routbort M; Herbrich SM; Baggerly K; Patel KP; Brusco L; Horombe C; Naing A; Fu S; Hong DS; Janku F; Johnson A; Broaddus R; Luthra R; Shaw K; Mendelsohn J; Mills GB; Meric-Bernstam F
Oncotarget; 2015 Aug; 6(24):20099-110. PubMed ID: 26015395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
